Erbitux (Head and Neck Cancer) Analysis and Forecasts to 2020


#28376

40pages

GlobalData

$ 2000

In Stock


Summary

GlobalDatas pharmaceuticals report, Erbitux (Head and Neck cancer)- Analysis and Forecasts to 2020 provides Erbitux sales forecasts for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2006-2020). The report also includes information on Head and Neck cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

 

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Erbitux including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Eribitux including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2006-2020 for Erbitux in each of the US and EU5.

Reasons to buy

 

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

 

Table of Content

 

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 Head and Neck Cancer Market 4
2.2 Epidemiology 4
2.3 Etiology 8
2.4 GlobalData Pipeline Report Guidance 9
Head and Neck Cancer Disease: Market Characterization 10
2.5 Head and Neck Cancer Disease Market 10
2.6 Head and Neck Cancer Disease Market Forecasts and CAGR 10
2.7 Drivers for the Head and Neck Cancer Disease Market 11
2.7.1 High Incidence 11
2.7.2 Low Initial Diagnosis Rate 12
2.7.3 Emergence of Targeted Therapies and Vaccines 12
Tumor NodeMetastases (TNM) Classification of Head and Neck Cancer 13
Erbitux 21
2.8 Introduction 21
2.9 Mechanism of Action 21
2.10 Clinical Studies 21
2.11 Approval History of Erbitux 22
2.12 Factors Affecting Sales of Erbitux 22
2.12.1 Head and Neck Cancer Market 22
2.12.2 Lower Efficacy in Locally Advanced Stage 22
2.12.3 Higher Efficacy in Metastatic Stage 23
2.12.4 Beneficial for both Locally Advanced and Metastatic Patients 23
2.12.5 Expensive Compared to Competitor 23
2.12.6 Presence in Market Prior to Head and Neck Cancer 23
2.12.7 Average Competition in Locally Advanced 23
2.12.8 Low Competition in Metastatic 23
2.12.9 Lower toxicity 23
2.13 Drug Risk Benefit Score 24
2.13.1 Drug Risk Benefit Score of Erbitux for Locally Advanced Head and Neck Cancer 24
2.13.2 Drug Risk Benefit Score of Erbitux for Metastatic Head and Neck Cancer 25
2.14 Intensity of Competition 26
2.15 Sales forecast 26
2.15.1 Target patient Pool of Erbitux 26
2.15.2 Dosing 27
2.15.3 Market Penetration 27
2.15.4 Annual Cost of Therapy 27
2.15.5 Sales Projections of Erbitux 28
Head and Neck Cancer Market: Appendix 36
2.16 Market Definitions 36
2.17 Abbreviations 36
2.18 Research Methodology 36
2.18.1 Coverage 37
2.18.2 Secondary Research 37
2.18.3 Forecasting 37
2.18.4 Number of Patients Approved to take the Drug 38
2.18.5 Net Penetration of Drug 38
2.18.6 Net Annual Dosing 39
2.18.7 Annual Cost of Therapy 39
2.18.8 Primary Research 39
2.18.9 Expert Panels 39
2.19 Contact Us 40
2.20 Disclaimer 40
2.21 Sources 40


Table 1: Head and Neck Cancer, Incidences and Mortality, 2008-2030 4
Table 2: Head and Neck Cancer, Global, Market Forecasts($bn), 20092020 10
Table 3: TNM Classification of the Oral cavity, Larynx, Oropharynx and Hypopharyngeal Cancers 13
Table 4: TNM Classification of the Nasopharyngeal Cancer 18
Table 5: Approval History of Erbitux 22
Table 6: Drug Risk Benefit Score of Erbitux for Locally Advanced 24
Table 7: Drug Risk Benefit Score of Erbitux for Metastatic 25
Table 8: Annual Cost of Therapy 28
Table 9: Head and Neck Cancer, Global, Estimated Sales of Erbitux ($m) 2006-2020 29
Table 10: Head and Neck Cancer, the US, Estimated Sales of Erbitux ($m) 2006-2020 30
Table 11: Head and Neck Cancer, the UK, EstimatedSales of Erbitux ($m) 2006-2020 31
Table 12: Head and Neck Cancer, France, Estimated Sales of Erbitux ($m) 2006-2020 32
Table 13: Head and Neck Cancer, Germany, Estimated Sales of Erbitux ($m) 2006-2020 33
Table 14: Head and Neck Cancer, Italy, Estimated Sales of Erbitux ($m) 2006-2020 34
Table 15: Head and Neck Cancer, Spain, Estimated Sales of Erbitux ($m) 2006-2020 35


Figure 1: Percentage Distribution of Top 20 Cancers, Based on Incidence Global, 2008 5
Figure 2: Percentage Distribution of Top 20 Cancers, Based on Mortality Global, 2008 6
Figure 3: Difference Between Percentage Distribution of Incidence and Mortality of Top 20 Cancers , 2008 7
Figure 4: Percentage Distribution of Various Cancer Types in Head and Neck Considering US, EU-5 and Japan Incidence, 2008 7
Figure 5: Percentage Distribution of Various Cancer Types in Head and Neck Considering Global Incidence, 2008 8
Figure 6: Per Capita Cigarette Consumption Curve, the US, 1976-2006 8
Figure 7: Head and Neck Cancer, Global, Market Forecasts ($bn), 20092020 10
Figure 8: Oncology Incidence (in billion), Global, 2008-2030 11
Figure 9: Head and Neck Cancer Incidence (in billion), Global, 2008-2030 11
Figure 10: Broad Classification of Head and Neck Cancer 12
Figure 11: Detailed TNM Classification of Oral Cavity Cancer 13
Figure 12: Detailed TNM Classification of Laryngeal Cancer 14
Figure 13: Detailed TNM Classification of Oropharyngeal Cancer 16
Figure 14: Detailed TNM Classification of Hypopharyngeal Cancer 16
Figure 15: Detailed TNM Classification of Nasopharyngeal Cancer 18
Figure 16: Classification of Head and Neck Cancer 19
Figure 17: Drug Model Diagram of Erbitux in the US and EU 27
Figure 18: Head and Neck Cancer, Global, Estimated Sales of Erbitux ($m) 2006-2020 29
Figure 19: Head and Neck Cancer, the US and EU, Erbitux Sales Distribution, 2014 29
Figure 20: Head and Neck Cancer, the US, Estimated Sales of Erbitux ($m) 2006-2020 30
Figure 21: Head and Neck Cancer, the UK, Estimated Sales of Erbitux ($m) 2006-2020 31
Figure 22: Head and Neck Cancer, France, Estimated Sales of Erbitux ($m) 2006-2020 32
Figure 23: Head and Neck Cancer, Germany, Estimated Sales of Erbitux ($m) 2006-2020 33
Figure 24: Head and Neck Cancer, Italy, Estimated Sales of Erbitux ($m) 2006-2020 34
Figure 25: Head and Neck Cancer, Spain, Estimated Sales of Erbitux ($m) 2006-2020 35
Figure 26: GlobalData Methodology 36
Figure 27: Drug Model Diagram 38
Figure 28: Patients Approved for the Drug 39